Biotech: SM vs MM

When comparing biotech-focused Single Managers (SMs) and Multi-Managers (MMs), there are several key factors to consider, including culture, compensation, deal access, and career trajectory. Here's a breakdown based on the most helpful WSO content:

1. Culture

• MMs: The culture at MMs is often described as fast-paced and high-pressure. MMs typically operate with a short-term, high-risk aversion strategy, focusing on quarterly earnings and relative value trades. This environment can be intense, with a strong emphasis on performance metrics and frequent portfolio rebalancing.
• SMs: SMs tend to have a more long-term investment horizon and are generally more tolerant of risk. The culture is often less transactional and more research-driven, with a focus on building deep expertise in specific sectors like biotech. This can lead to a more collaborative and less cutthroat environment compared to MMs.

2. Compensation

• MMs: Compensation at top MMs (e.g., Citadel, Point72, Millennium) can be highly lucrative, especially for top performers. However, it is closely tied to fund performance and individual contribution. High turnover is common, as underperformance can lead to quick exits.
• SMs: While SMs may offer slightly lower base compensation compared to MMs, the upside potential can be significant, especially for those who rise to senior roles. Compensation is often more stable and less tied to short-term performance metrics.

3. PIPE/Cross-Over Deal Access

• MMs: MMs are generally less involved in PIPE (Private Investment in Public Equity) and cross-over deals due to their shorter investment horizons and focus on public markets. Their strategies are more aligned with trading and relative value opportunities.
• SMs: SMs, particularly those with a biotech focus, are more likely to participate in PIPE and cross-over deals. These deals align with their long-term investment strategies and provide opportunities to build relationships with biotech companies at earlier stages.

4. Career Trajectory

• MMs: Starting at an MM can provide strong training in modeling, risk management, and trading strategies. However, the skill set developed at MMs is often seen as less transferable to SMs due to the differences in investment approach. Moving from an MM to an SM can be challenging, as SMs may view MM experience as too short-term focused.
• SMs: Working at an SM can position you well for a long-term career in biotech investing. The skills and relationships developed at SMs are often more aligned with the needs of other SMs or even venture capital and private equity roles.

5. Is It Worth Taking a Shot at MMs?

• If your goal is to build a career in biotech investing with a long-term focus, starting at an SM may be a better fit. However, if you are looking for a fast-paced environment with potentially higher short-term earnings, an MM could be a good choice.
• Keep in mind that moving from an MM to an SM can be difficult, as the skill sets and investment philosophies differ significantly. Many investors view MMs as more transactional, which may not align with the research-driven approach of SMs.

6. Polarization Among Investors

• The polarization stems from the fundamental differences in investment philosophy. SM proponents often view MMs as overly focused on short-term gains, while MM advocates may see SMs as slower-moving and less adaptable. Ultimately, the choice depends on your personal preferences, career goals, and risk tolerance.

In summary, if you value long-term investing, deeper sector expertise, and a more stable career trajectory, SMs may be the better option. On the other hand, if you thrive in a high-pressure, performance-driven environment and are drawn to the potential for high short-term earnings, MMs could be worth considering.

Sources: Most respected funds out there?, Point72 Academy SA 2021, Point 72 vs Blackstone, Performance of the best PM’s at MM’s?, MM to SM is it possible